Mr. Speaker, we are working very closely with the medical isotopes experts on this issue. We are looking at identifying alternatives which have already been identified and are on the market, and are available for use by the provinces and territories. When we are dealing with a small supply of medical isotopes, it is very important to manage one's cases with one's patients and examine what options are available as alternatives.
That is the information we have provided to the provinces and territories, and to care providers in the provinces.